Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02706951) looked at upadacitinib compared to methotrexate in people with rheumatoid arthritis. The trial ran in two periods. In the first period, 216 participants were assigned to methotrexate, 217 to upadacitinib 15 mg, and 215 to upadacitinib 30 mg. In the second period, 302 participants continued or switched to upadacitinib 15 mg and 300 to upadacitinib 30 mg. The trial was measuring things like joint tenderness and swelling, overall disease activity scores, physical function, and quality of life — all assessed at 14 weeks. The reported data shows the following at the 14-week mark. For the main measurement used for US regulators — the proportion of participants whose joint counts and other markers improved by at least 20% — 41.2% of the methotrexate group, 67.7% of the upadacitinib 15 mg group, and 71.2% of the upadacitinib 30 mg group met that threshold. For the main measurement used for European regulators — the proportion reaching "low disease activity" on a standard scoring scale — the reported figures were 19.4%, 44.7%, and 53.0% respectively. The proportion recorded as reaching "clinical remission" on that same scale was 8.3%, 28.1%, and 40.5% across the three groups. The reported data also shows changes in several secondary measures at 14 weeks. On a disease activity score (ranging roughly 0–10, where lower is better), the average change from the starting score was −1.20 for methotrexate, −2.29 for upadacitinib 15 mg, and −2.61 for upadacitinib 30 mg. On a physical function questionnaire (0–3 scale, where lower means less difficulty), the reported average changes were −0.32, −0.65, and −0.73. On a general physical quality-of-life score (where higher is better), the average improvements reported were 4.32, 8.28, and 10.19 points respectively. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 40875187) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Rheumatoid Arthritis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with rheumatoid arthritis (RA) for at least 3 months.
- You have been taking methotrexate (MTX) pills or injections for at least 3 months, and your dose has stayed the same for at least 4 weeks before starting the trial.
- You have stopped taking all other standard RA medications (apart from methotrexate) at least 4 weeks before starting the trial.
- At your screening and baseline appointments, you have at least 6 swollen joints and at least 6 tender joints, showing that your RA is currently active.
Who may not be able to join:
- You have previously taken any JAK inhibitor medication, such as tofacitinib, baricitinib, or filgotinib.
- You have previously been treated with any biological RA medications (sometimes called "biologics").
- You currently have another inflammatory joint condition in addition to RA — although having secondary Sjögren's Syndrome alongside RA is allowed (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: AbbVie Inc., AbbVie
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14; Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 14
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.